GSK to acquire Nuvalent for $11 billion, adding two lung-cancer drugs under FDA review

GSK announced a deal to buy Massachusetts‑based biotech Nuvalent for $11 billion. The acquisition brings two experimental lung‑cancer medicines that are currently under review by the U.S. Food and Drug Administration.

The drugs target tumors with ROS1 and ALK mutations, offering potential alternatives to existing treatments such as Xalkori. Nuvalent hopes the new agents will provide more durable responses, reduced resistance and fewer side effects.

GSK plans to use the two candidates to build a broader franchise of lung‑cancer therapies and may expand the portfolio further if a dual‑acting therapy under development receives approval.

Under the terms of the transaction, GSK will pay Nuvalent shareholders $124 per share, representing a 40% premium to the previous closing price.